SCHEMBL13815320

SCHEMBL13815320

CC(=O)CNCCC(C)C

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
ANPEP P15144 4/20 0.37
RNPEP Q9H4A4 3/20 0.37
DNPEP Q9ULA0 3/20 0.37
CA1 P00915 2/20 0.36
SMN1; SMN2 Q16637 4/20 0.35
RAB9A P51151 3/20 0.35
GAA P10253 1/20 0.35
KISS1R Q969F8 1/20 0.34
NPC1 O15118 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CNR1 P21554 1/20 0.33
LMNA P02545 1/20 0.32
PKM P14618 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL288760 0.81 ALDH1A1 (0.40) ALDH1A1TDP1ANPEPRNPEPDNPEP
SCHEMBL22677513 0.80 USP2 (0.31) ALDH1A1TDP1CA1
SCHEMBL8338768 0.79 MAOA (0.47) ALDH1A1ANPEPRNPEPDNPEPCA1
SCHEMBL20085628 0.79 PAOX (0.39) ALDH1A1TDP1ANPEPRNPEPDNPEP
SCHEMBL25159888 0.77 ANPEP (0.35) ALDH1A1ANPEPRNPEPDNPEPCA1
SCHEMBL5538723 0.77 TET2 (0.39) ANPEPRNPEPDNPEPSMN1; SMN2RAB9A
SCHEMBL24508253 0.76 RARB (0.34) ALDH1A1SMN1; SMN2KISS1R
SCHEMBL16213675 0.76 LMNA (0.30) LMNA
SCHEMBL25453161 0.74 ALDH1A1 (0.33) ALDH1A1TDP1
SCHEMBL21335952 0.74 GSR (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230292741-A1 NOVEL SUPERCOOLING METHODS FOR PRESERVATION OF BIOLOGICAL SAMPLES X-THERMA, INC. (US) 2023-09-21 US disclosed
US-20180111905-A1 N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2018-04-26 US disclosed
US-20150031743-A1 CELL TRANSFECTING FORMULATIONS OF SMALL INTERFERING RNA, RELATED COMPOSITIONS AND METHODS OF MAKING AND USE NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2015-01-29 US disclosed
US-8772255-B2 Cell transfecting formulations of small interfering RNA related compositions and methods of making and use NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2014-07-08 US disclosed
US-20090143322-A1 CELL TRANSFECTING FORMULATIONS OF SMALL INTERFERING RNA RELATED COMPOSITIONS AND METHODS OF MAKING AND USE CHIRON CORPORATION (US) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180111905-A1 N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT ALK, NPM1, EML4 ALDH1A1 1803/4885TDP1 1272/4885ANPEP 120/4885
US-20090143322-A1 CELL TRANSFECTING FORMULATIONS OF SMALL INTERFERING RNA RELATED COMPOSITIONS AND METHODS OF MAKING AND USE SNRPE, SNRPA, PHAX ALDH1A1 4470/4885TDP1 2572/4885ANPEP 2842/4885
US-20150031743-A1 CELL TRANSFECTING FORMULATIONS OF SMALL INTERFERING RNA, RELATED COMPOSITIONS AND METHODS OF MAKING AND USE SNRPE, PHAX, SNRPA ALDH1A1 4443/4885TDP1 2518/4885ANPEP 2876/4885
US-20230292741-A1 NOVEL SUPERCOOLING METHODS FOR PRESERVATION OF BIOLOGICAL SAMPLES PPIG, AQP3, AQP1 ALDH1A1 4823/4885TDP1 888/4885ANPEP 1611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.